New CFO Appointment: Quoin Pharmaceuticals has appointed Sally Lawlor as the new Chief Financial Officer to support the company's growth and advancement of its lead product candidate, QRX003.
Experience of New CFO: Ms. Lawlor brings over 20 years of financial leadership experience from her previous roles at Sebela Pharmaceuticals, Aptiv Plc, and KPMG, focusing on global tax strategy and compliance.
Clinical Studies Update: Quoin is conducting pivotal clinical studies for QRX003 in Netherton Syndrome, with full enrollment expected by early to mid-Q1 2026, while also developing programs for other rare dermatologic diseases.
Company's Mission: Quoin Pharmaceuticals aims to address unmet medical needs for patients with rare and orphan diseases through its innovative pipeline, which includes multiple therapeutic products in development.
QNRX
$11.72+Infinity%1D
Analyst Views on QNRX
Wall Street analysts forecast QNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNRX is 70.00 USD with a low forecast of 70.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast QNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNRX is 70.00 USD with a low forecast of 70.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.270
Low
70.00
Averages
70.00
High
70.00
Current: 10.270
Low
70.00
Averages
70.00
High
70.00
No data
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
